185750.KS
Chong Kun Dang Pharmaceutical Corp. [185750.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
185750.KS Stock Summary
Top 10 Correlated ETFs
185750.KS
Top 10 Correlated Stocks
185750.KS
In the News
185750.KS Financial details
Company Rating
Strong Buy
Market Cap
1305.83B
Income
212.52B
Revenue
1669.4B
Book val./share
64101.28
Cash/share
28688.62
Dividend
907.03
Dividend %
0.77%
Employees
2.29K
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
16.18
Forward P/E
12.39
PEG
1.06
P/S
0.97
P/B
3.01
P/C
3.48
P/FCF
28.52
Quick Ratio
-
Current Ratio
1.68
Debt / Equity
0.26
LT Debt / Equity
0.04
-
-
EPS (TTM)
16.67K
EPS next Y
8065.33
EPS next Q
-
EPS this Y
152.76%
EPS next Y
-51.63%
EPS next 5Y
-
EPS last 5Y
31.18%
Revenue last 5Y
9.11%
Revenue Q/Q
25.03%
EPS Q/Q
93.95%
-
-
-
-
SMA20
-5.52%
SMA50
-8.7%
SMA100
-10.84%
Inst Own
-
Inst Trans
-
ROA
11%
ROE
20%
ROC
0.19%
Gross Margin
37%
Oper. Margin
10%
Profit Margin
9%
Payout
-
Shs Outstand
12.7M
Shs Float
6.74M
-
-
-
-
Target Price
-
52W Range
69428.57-136500.0
52W High
-26.81%
52W Low
+43.89%
RSI
33.39
Rel Volume
0.68
Avg Volume
45.87K
Volume
31.29K
Perf Week
-4.49%
Perf Month
-6.64%
Perf Quarter
13.28%
Perf Half Y
4.69%
-
-
-
-
Beta
0.912
-
-
Volatility
1789.99%, 4001.38%
Prev Close
0.3%
Price
99900
Change
-2.06%
185750.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 86.14K | 104.06K | 108.01K | 121.5K | 131.21K | |
| Net income per share | 4.3K | 7.32K | 3.43K | 6.61K | 16.7K | |
| Operating cash flow per share | 6.17K | 8.33K | 1.04K | 5.53K | 25.01K | |
| Free cash flow per share | 4.18K | 5.39K | -3.13K | 1.2K | 19.6K | |
| Cash per share | 7.37K | 12.93K | 15.06K | 12.72K | 28.69K | |
| Book value per share | 37.79K | 44.04K | 45.5K | 50.81K | 64.11K | |
| Tangible book value per share | 36.64K | 42.53K | 43.81K | 48.52K | 59.98K | |
| Share holders equity per share | 37.79K | 44.04K | 45.5K | 50.81K | 64.11K | |
| Interest debt per share | 9.67K | 11.18K | 19.38K | 19.8K | 17.61K | |
| Market cap | 999.87B | 2450.09B | 1252.42B | 937.95B | 1637.41B | |
| Enterprise value | 1041B | 2462.57B | 1357.66B | 1056.27B | 1637.52B | |
| P/E ratio | 18.56 | 26.74 | 29.32 | 11.59 | 7.7 | |
| Price to sales ratio | 0.93 | 1.88 | 0.93 | 0.63 | 0.98 | |
| POCF ratio | 12.94 | 23.49 | 97.06 | 13.85 | 5.15 | |
| PFCF ratio | 19.07 | 36.29 | -32.16 | 63.94 | 6.57 | |
| P/B Ratio | 2.11 | 4.44 | 2.21 | 1.51 | 2.01 | |
| PTB ratio | 2.11 | 4.44 | 2.21 | 1.51 | 2.01 | |
| EV to sales | 0.96 | 1.89 | 1.01 | 0.71 | 0.98 | |
| Enterprise value over EBITDA | 10.36 | 16.37 | 12.02 | 7.29 | 5.77 | |
| EV to operating cash flow | 13.47 | 23.61 | 105.21 | 15.59 | 5.15 | |
| EV to free cash flow | 19.86 | 36.48 | -34.87 | 72 | 6.57 | |
| Earnings yield | 0.05 | 0.04 | 0.03 | 0.09 | 0.13 | |
| Free cash flow yield | 0.05 | 0.03 | -0.03 | 0.02 | 0.15 | |
| Debt to equity | 0.25 | 0.25 | 0.42 | 0.38 | 0.26 | |
| Debt to assets | 0.15 | 0.14 | 0.23 | 0.21 | 0.15 | |
| Net debt to EBITDA | 0.41 | 0.08 | 0.93 | 0.82 | 0 | |
| Current ratio | 1.7 | 1.87 | 2.08 | 1.91 | 1.85 | |
| Interest coverage | 23.67 | 32.02 | 23.51 | 16.05 | 26.61 | |
| Income quality | 1.46 | 1.15 | 0.3 | 0.85 | 1.5 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.16 | 0.1 | 0.25 | 0.14 | 0.05 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Research and developement to revenue | 0.09 | 0.11 | 0.12 | 0.12 | 0.08 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | |
| Capex to operating cash flow | -0.32 | -0.35 | -4.02 | -0.78 | -0.22 | |
| Capex to revenue | -0.02 | -0.03 | -0.04 | -0.04 | -0.04 | |
| Capex to depreciation | -1.08 | -1.55 | -1.89 | -1.58 | -1.86 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 60.47K | 85.15K | 59.29K | 86.92K | 155.23K | |
| ROIC | 0.09 | 0.13 | 0.06 | 0.11 | 0.21 | |
| Return on tangible assets | 0.07 | 0.1 | 0.04 | 0.07 | 0.16 | |
| Graham Net | -447.45 | 2.41K | -415.49 | 227.59 | 11.21K | |
| Working capital | 194.07B | 279.49B | 346.92B | 339.4B | 435.11B | |
| Tangible asset value | 459.04B | 532.56B | 545B | 594.34B | 763.11B | |
| Net current asset value | 144.74B | 205.37B | 186.26B | 210.02B | 359.78B | |
| Invested capital | 0.25 | 0.25 | 0.42 | 0.38 | 0.26 | |
| Average receivables | 211.19B | 216.27B | 230.83B | 261.01B | 299.39B | |
| Average payables | 85.28B | 123.04B | 136.72B | 137.38B | 164.69B | |
| Average inventory | 138.02B | 167.01B | 205.14B | 247.4B | 265.76B | |
| Days sales outstanding | 69.52 | 63.58 | 63.76 | 70.46 | 68.1 | |
| Days payables outstanding | 55.13 | 64.63 | 55.68 | 56.13 | 66.21 | |
| Days of inventory on hand | 80.27 | 83.22 | 96.76 | 104.24 | 94.1 | |
| Receivables turnover | 5.25 | 5.74 | 5.72 | 5.18 | 5.36 | |
| Payables turnover | 6.62 | 5.65 | 6.55 | 6.5 | 5.51 | |
| Inventory turnover | 4.55 | 4.39 | 3.77 | 3.5 | 3.88 | |
| ROE | 0.11 | 0.17 | 0.08 | 0.13 | 0.26 | |
| Capex per share | -1.98K | -2.94K | -4.17K | -4.33K | -5.41K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 31.02K | 28.59K | 31.03K | 31.65K | 39.65K | |
| Net income per share | 924.32 | 2.81K | 3.36K | 3.58K | 6.94K | |
| Operating cash flow per share | 2.34K | 3.33K | 3.89K | 6.65K | 11.1K | |
| Free cash flow per share | 632.82 | 2.46K | 1.66K | 5.81K | 9.64K | |
| Cash per share | 12.18K | 14.31K | 14.58K | 19.1K | 28.69K | |
| Book value per share | 48.63K | 50.26K | 53.76K | 57.34K | 64.1K | |
| Tangible book value per share | 46.44K | 47.9K | 50.13K | 53.54K | 59.97K | |
| Share holders equity per share | 48.63K | 50.26K | 53.76K | 57.34K | 64.1K | |
| Interest debt per share | 18.59K | 19.27K | 18.78K | 17.53K | 17.07K | |
| Market cap | 979.99B | 943.93B | 997.84B | 1139.08B | 1637.72B | |
| Enterprise value | 1098.31B | 1036.94B | 1089.01B | 1134.25B | 1637.84B | |
| P/E ratio | 20.71 | 6.58 | 5.83 | 6.25 | 4.64 | |
| Price to sales ratio | 2.47 | 2.58 | 2.52 | 2.82 | 3.25 | |
| POCF ratio | 32.72 | 22.18 | 20.08 | 13.44 | 11.6 | |
| PFCF ratio | 121 | 30.02 | 47.05 | 15.38 | 13.35 | |
| P/B Ratio | 1.57 | 1.47 | 1.45 | 1.56 | 2.01 | |
| PTB ratio | 1.57 | 1.47 | 1.45 | 1.56 | 2.01 | |
| EV to sales | 2.77 | 2.84 | 2.75 | 2.81 | 3.25 | |
| Enterprise value over EBITDA | 38.69 | 24.48 | 7.54 | 7.57 | 13.26 | |
| EV to operating cash flow | 36.67 | 24.37 | 21.92 | 13.39 | 11.6 | |
| EV to free cash flow | 135.61 | 32.98 | 51.35 | 15.32 | 13.35 | |
| Earnings yield | 0.01 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Free cash flow yield | 0.01 | 0.03 | 0.02 | 0.07 | 0.07 | |
| Debt to equity | 0.38 | 0.38 | 0.35 | 0.3 | 0.26 | |
| Debt to assets | 0.21 | 0.21 | 0.2 | 0.17 | 0.15 | |
| Net debt to EBITDA | 4.17 | 2.2 | 0.63 | -0.03 | 0 | |
| Current ratio | 1.91 | 1.84 | 2.1 | 1.68 | 1.85 | |
| Interest coverage | 8.71 | 13.87 | 19.7 | 24.38 | 47.07 | |
| Income quality | 2.55 | 1.18 | 1.15 | 1.83 | 1.6 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.27 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.25 | 0.23 | 0.01 | |
| Research and developement to revenue | 0.15 | 0.1 | 0.08 | 0.07 | 0.09 | |
| Intangibles to total assets | 0.02 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Capex to operating cash flow | -0.73 | -0.26 | -0.57 | -0.13 | -0.13 | |
| Capex to revenue | -0.06 | -0.03 | -0.07 | -0.03 | -0.04 | |
| Capex to depreciation | -2.51 | -1.22 | -3.07 | -1.12 | -2.04 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 31.8K | 56.34K | 63.71K | 67.92K | 100.01K | |
| ROIC | 0.02 | 0.04 | 0.05 | 0.05 | 0.09 | |
| Return on tangible assets | 0.01 | 0.03 | 0.04 | 0.04 | 0.07 | |
| Graham Net | 217.83 | 471.84 | 2.63K | 5.24K | 11.21K | |
| Working capital | 339.4B | 340.8B | 388.97B | 331.75B | 435.11B | |
| Tangible asset value | 594.34B | 611.77B | 639.74B | 682.62B | 763.11B | |
| Net current asset value | 210.02B | 217.07B | 242.76B | 281.33B | 359.78B | |
| Invested capital | 0.38 | 0.38 | 0.35 | 0.3 | 0.26 | |
| Average receivables | 275.43B | 284.09B | 278.98B | 286.87B | 304.06B | |
| Average payables | 141.76B | 149.96B | 148.43B | 169.4B | 190.19B | |
| Average inventory | 270.33B | 275.53B | 280.02B | 279.61B | 270.8B | |
| Days sales outstanding | 65.12 | 69.22 | 62.97 | 66.15 | 55.55 | |
| Days payables outstanding | 51.4 | 60.53 | 50.91 | 69.66 | 60.47 | |
| Days of inventory on hand | 95.46 | 110.09 | 99.8 | 99.36 | 85.95 | |
| Receivables turnover | 1.38 | 1.3 | 1.43 | 1.36 | 1.62 | |
| Payables turnover | 1.75 | 1.49 | 1.77 | 1.29 | 1.49 | |
| Inventory turnover | 0.94 | 0.82 | 0.9 | 0.91 | 1.05 | |
| ROE | 0.02 | 0.06 | 0.06 | 0.06 | 0.11 | |
| Capex per share | -1.71K | -869.56 | -2.23K | -838.17 | -1.46K |
185750.KS Frequently Asked Questions
What is Chong Kun Dang Pharmaceutical Corp. stock symbol ?
Chong Kun Dang Pharmaceutical Corp. is a KR stock and trading under the symbol 185750.KS
What is Chong Kun Dang Pharmaceutical Corp. stock quote today ?
Chong Kun Dang Pharmaceutical Corp. stock price is $99900 today.
Is Chong Kun Dang Pharmaceutical Corp. stock public?
Yes, Chong Kun Dang Pharmaceutical Corp. is a publicly traded company.
Company Profile
- Volume Average 45.87K
- Market Capitalization 1305.83B
- Employee 2.29K
- CEO Mr. Young-Joo Kim
- Headquarters Seoul,KR
- IPO Date 2013-12-06
-
Website
https://www.ckdpharm.com 
Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
